Mall PA
MOTS-c NOT FOR HUMANS BANNED IN TESTED SPORT
File 05 · mitochondrial-derived peptide (16 amino acids) encoded in mitochondrial DNA

MOTS-c

Also called: mitochondrial open reading frame of the 12S rRNA-c, mitochondrial-derived peptide MOTS-c

Banned · S4None

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, discovered in 2015. In animal work it acts largely on skeletal muscle and switches on AMPK, a cellular energy sensor that exercise also activates.

Why the gym talks about it

It is marketed as an 'exercise mimetic' or 'exercise in a vial' for fat loss, endurance and metabolic health. The nickname comes from mouse data, not human trials.

What the research actually found

  • animal (mouse) and cell studiesIn mice, MOTS-c treatment prevented age-related and high-fat-diet-induced insulin resistance and diet-induced obesity, acting mainly on skeletal muscle through AMPK activation. Source
  • animal (mouse)MOTS-c improved physical performance in young, middle-aged and old mice, and treatment begun late in life increased physical capacity in old mice. Source
  • human observational (endogenous levels)In humans, exercise raised the body's own MOTS-c in skeletal muscle and in blood. This shows the peptide responds to exercise; it does not show that injecting it reproduces exercise benefits. Two senior authors disclosed consulting for and holding shares in a company developing MOTS-c-based drugs. Source

Human evidence: none. No published randomized trials of administered MOTS-c in humans; human data only measure the body's own MOTS-c levels.

Tested lifters

S4.4.1 Metabolic Modulators (AMPK activators). MOTS-c is named alongside AICAR; prohibited at all times.

High. It is explicitly listed. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

Not FDA-approved. MOTS-c was in Category 2 of the interim 503A list, was removed from Category 2 on April 15, 2026 (not yet eligible for compounding), and on July 23, 2026 the Pharmacy Compounding Advisory Committee voted 7-5 (2 abstentions) to recommend it for the 503A bulks list (nominated for obesity and osteoporosis). No final FDA action has been found as of Oct 1, 2026.

As of 2026-10-01.

Known and theoretical risks

  • FDA cites possible significant immune reactions by some routes of administration, plus product-quality complexities. Source
  • No human dose-response or long-term safety data exist for administered MOTS-c. Source

Quick answers

Is MOTS-c banned for drug-tested lifters?

S4.4.1 Metabolic Modulators (AMPK activators). MOTS-c is named alongside AICAR; prohibited at all times. High. It is explicitly listed. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is MOTS-c FDA approved?

Not FDA-approved. MOTS-c was in Category 2 of the interim 503A list, was removed from Category 2 on April 15, 2026 (not yet eligible for compounding), and on July 23, 2026 the Pharmacy Compounding Advisory Committee voted 7-5 (2 abstentions) to recommend it for the 503A bulks list (nominated for obesity and osteoporosis). No final FDA action has been found as of Oct 1, 2026.

How strong is the human evidence for MOTS-c?

None. No published randomized trials of administered MOTS-c in humans; human data only measure the body's own MOTS-c levels.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement